BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma C, Battat R, Parker CE, Khanna R, Jairath V, Feagan BG. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease? Expert Review of Gastroenterology & Hepatology 2019;13:319-30. [DOI: 10.1080/17474124.2019.1563481] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Niu M, Chen Z, Li M, Zhang X, Chen C, Rufo PA. Differentiation of Isolated Small Bowel Crohn’s Disease from Other Small Bowel Ulcerative Diseases: Clinical Features and Double-Balloon Enteroscopy Characteristics. Gastroenterology Research and Practice 2022;2022:1-13. [DOI: 10.1155/2022/5374780] [Reference Citation Analysis]
2 Revés J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov 2021;2:100070. [PMID: 34988431 DOI: 10.1016/j.crphar.2021.100070] [Reference Citation Analysis]
3 Pérez de Arce E, Quera R, Quigley EMM. The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. Gastroenterol Clin North Am 2021;50:689-711. [PMID: 34304795 DOI: 10.1016/j.gtc.2021.03.008] [Reference Citation Analysis]
4 Con D, van Langenberg DR, Vasudevan A. Deep learning vs conventional learning algorithms for clinical prediction in Crohn's disease: A proof-of-concept study. World J Gastroenterol 2021; 27(38): 6476-6488 [PMID: 34720536 DOI: 10.3748/wjg.v27.i38.6476] [Reference Citation Analysis]
5 Nardone OM, Shivaji UN, Ferruzza V, Ghosh S, Iacucci M. Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. Inflamm Bowel Dis 2020;26:961-9. [PMID: 31587036 DOI: 10.1093/ibd/izz226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Nardone OM, Calabrese G, Testa A, Caiazzo A, Fierro G, Rispo A, Castiglione F. The Impact of Intestinal Ultrasound on the Management of Inflammatory Bowel Disease: From Established Facts Toward New Horizons. Front Med 2022;9:898092. [DOI: 10.3389/fmed.2022.898092] [Reference Citation Analysis]
7 Ismail MS, Semenov S, McNamara D. The utility of faecal and urine biomarkers for small bowel diseases. Curr Opin Gastroenterol 2021;37:284-94. [PMID: 33769381 DOI: 10.1097/MOG.0000000000000730] [Reference Citation Analysis]
8 Wilkens R, Novak KL, Maaser C, Panaccione R, Kucharzik T. Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives. Therap Adv Gastroenterol 2021;14:17562848211006672. [PMID: 33948115 DOI: 10.1177/17562848211006672] [Reference Citation Analysis]
9 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterol Hepatol 2021;44:312-9. [PMID: 33070988 DOI: 10.1016/j.gastrohep.2020.06.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Atreya R, Neurath MF, Siegmund B. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? Front Med (Lausanne) 2020;7:517. [PMID: 32984386 DOI: 10.3389/fmed.2020.00517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
11 Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol 2020;5:819-28. [PMID: 32553149 DOI: 10.1016/S2468-1253(20)30188-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 10.5] [Reference Citation Analysis]
12 Kraszewski S, Szczurek W, Szymczak J, Reguła M, Neubauer K. Machine Learning Prediction Model for Inflammatory Bowel Disease Based on Laboratory Markers. Working Model in a Discovery Cohort Study. J Clin Med 2021;10:4745. [PMID: 34682868 DOI: 10.3390/jcm10204745] [Reference Citation Analysis]
13 Kim ES. Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease. Gut Liver 2021;15:637-8. [PMID: 34521774 DOI: 10.5009/gnl210393] [Reference Citation Analysis]
14 Ponorac S, Dahmane Gošnak R, Urlep D, Ključevšek D. Diagnostic Value of Quantitative Contrast-Enhanced Ultrasound in Comparison to Endoscopy in Children with Crohn's Disease. J Ultrasound Med 2022. [PMID: 35748308 DOI: 10.1002/jum.16044] [Reference Citation Analysis]
15 Ma C, Pai RK, Schaeffer DF, Krell J, Guizzetti L, McFarlane SC, MacDonald JK, Choi WT, Feakins RM, Kirsch R, Lauwers GY, Pai RK, Rosty C, Srivastava A, Walsh JC, Feagan BG, Jairath V. Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis. J Immunother Cancer 2022;10:e004560. [PMID: 35296560 DOI: 10.1136/jitc-2022-004560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Smits LJT, Pauwels RWM, Kievit W, de Jong DJ, de Vries AC, Hoentjen F, van der Woude CJ; LADI study group. Lengthening adalimumab dosing interval in quiescent Crohn's disease patients: protocol for the pragmatic randomised non-inferiority LADI study. BMJ Open 2020;10:e035326. [PMID: 32461297 DOI: 10.1136/bmjopen-2019-035326] [Reference Citation Analysis]
17 F M, D M, M P, B A, P L, I R, Ht S, P M, I M, A V, J C, J M, J R, C E, P S, F P, L C, M S, S D, C A, J A, S D, L PB, Cc D; GEDII. Subclinical Persistent Inflammation as risk factor for Crohn's Disease progression: findings from a prospective real-world study of 2 years. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01298-2. [PMID: 34896644 DOI: 10.1016/j.cgh.2021.12.004] [Reference Citation Analysis]
18 Kumar A, Lukin DJ. Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2020;32:205-15. [PMID: 31851091 DOI: 10.1097/MEG.0000000000001648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sharma V, Verma S, Kumar-m P, Mandavdhare HS, Singh H, Shah J, Kalsi D, Dutta A, Mishra S, Prasad KK, Sharma AK, Dutta U. Serial measurements of faecal calprotectin may discriminate intestinal tuberculosis and Crohn’s disease in patients started on antitubercular therapy. European Journal of Gastroenterology & Hepatology 2021;33:334-8. [DOI: 10.1097/meg.0000000000001879] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Mahalingam N, Tkach JA, Denson LA, Dillman JR. Bowel wall MRI T1 relaxation estimates for assessment of intestinal inflammation in pediatric Crohn's disease. Abdom Radiol (NY) 2022. [PMID: 35657390 DOI: 10.1007/s00261-022-03560-y] [Reference Citation Analysis]
21 Słowińska-Solnica K, Pawlica-Gosiewska D, Gawlik K, Owczarek D, Cibor D, Pocztar H, Mach T, Solnica B. Serum inflammatory markers in the diagnosis and assessment of Crohn's disease activity. Arch Med Sci 2021;17:252-7. [PMID: 33488879 DOI: 10.5114/aoms/130842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wu Y, Wang Z, Xing M, Li B, Liu Z, Du P, Yang H, Wang X. The Specific Changes of Urine Raman Spectra Can Serve as Novel Diagnostic Tools for Disease Characteristics in Patients with Crohn’s Disease. JIR 2022;Volume 15:897-910. [DOI: 10.2147/jir.s341871] [Reference Citation Analysis]